Desvenlafaxine ER
Total Payments
$401,231
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $401,231 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $401,231 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| DESV-16045 | Mylan Pharmaceuticals Inc. | $261,787 | 0 |
| DESV-16044 | Mylan Pharmaceuticals Inc. | $139,444 | 0 |
Top Doctors Receiving Payments for Desvenlafaxine ER
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Austin, TX | $401,231 | 4 |
Ad
Manufacturing Companies
- Mylan Pharmaceuticals Inc. $401,231
Product Information
- Type Drug
- Total Payments $401,231
- Total Doctors 0
- Transactions 4
About Desvenlafaxine ER
Desvenlafaxine ER is a drug associated with $401,231 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Mylan Pharmaceuticals Inc..
Payment data is available from 2017 to 2017. In 2017, $401,231 was paid across 4 transactions to 0 doctors.
The most common payment nature for Desvenlafaxine ER is "Unspecified" ($401,231, 100.0% of total).
Desvenlafaxine ER is associated with 2 research studies, including "DESV-16045" ($261,787).